- Supported exchanges /
- IC /
- OCS.IC
Oculis Holding AG (OCS IC) stock market data APIs
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Oculis Holding AG Financial Data Overview
| 2220.5 | |
| 2140.35 | |
| - | |
| 2219.5 | |
| 2139.81 | |
| 1500-2500 | |
| 0 | |
| 0 | |
| 0 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Oculis Holding AG Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Oculis Holding AG Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Oculis Holding AG End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
